DelveInsight’s “Acute Pancreatitis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute Pancreatitis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Acute Pancreatitis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Acute Pancreatitis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Acute Pancreatitis: An Overview
Acute pancreatitis (AP) is characterized by inflammation of the exocrine pancreas which occurs as a result of auto-digestion of the pancreas by pancreatic enzymes. AP is associated with acinar cell injury and both a local and systemic inflammatory response. The incidence of Acute Pancreatitis has been increasing worldwide, but the major etiologies remain gallstones and alcohol.
According to The National Pancreas Foundation, Acute Pancreatitis is an inflammatory condition of the pancreas that is painful and deadly. Despite the great advances in critical care medicine over the past 20 years, the Acute Pancreatitis mortality rate has remained at about 10%. Diagnosis of pancreatic problems is often difficult, and treatments are delayed because the organ is relatively inaccessible. There are no easy ways to see the pancreas directly without surgery, and available imaging studies are often inadequate. In addition to the acute form, there are hereditary and chronic forms of pancreatitis that can devastate a person over many years. Sufferers often endure pain and malnutrition and are most likely left with a higher risk of pancreatic cancer.
Acute Pancreatitis Market Key Facts
The United States accounted for the largest market size of Acute Pancreatitis (Almost USD 500 Million) in 2021, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
Among EU5 countries, Germany, had the largest Acute Pancreatitis market size with ~USD 50 Million, while Italy had the smallest market size of almost USD 10 Million in 2021.
Japan had a market size of nearly USD 45 Million, in 2021.
The total 7MM incident cases of Acute Pancreatitis (AP) in 2021 were approximately 500,000 out of which the highest incident cases of this disease were seen in the United States.
EU-5 countries accounted for approximately 160,000 cases in 2021.
In 2021, the incident cases of Acute Pancreatitis in the United States were ~280,000 cases which, as per DelveInsight’s estimates, are expected to increase in the study period (2019-2032).
In 2021, the incident population of Acute Pancreatitis in Japan was nearly 62,000.
The estimates suggest that the gender-based incidence varied in the 7MM with the male incident cases higher in the United Kingdom, Japan, and Germany, whereas in the United States, the female incident cases were higher.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Acute Pancreatitis pipeline therapies. It also thoroughly assesses the Acute Pancreatitis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Acute Pancreatitis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Acute Pancreatitis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Acute Pancreatitis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Acute Pancreatitis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Acute Pancreatitis Epidemiology, Segmented as –
Incident Cases of Acute Pancreatitis
Etiology-specific cases of Acute Pancreatitis
Severity-specific cases of Acute Pancreatitis
Gender-specific cases of Acute Pancreatitis
Recurrent cases of Acute Pancreatitis
Acute Pancreatitis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Acute Pancreatitis market or expected to be launched during the study period. The analysis covers the Acute Pancreatitis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Acute Pancreatitis drugs based on their sale and market share.
The report also covers the Acute Pancreatitis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Acute Pancreatitis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Acute Pancreatitis Market Will Evolve and Grow by 2032 @
Acute Pancreatitis Therapeutics Analysis
The management of acute pancreatitis depends on the severity of the disease and the concomitant complications that may arise. The treatment approach is usually based on the extent of severity and the underlying cause of the disease. The primary goal of the treatment is to relieve the pain and reduce the inflammation associated with the Pancreas. Currently, there is no therapy that is approved by the FDA to treat Acute Pancreatitis, therefore the treatment generally focuses on relieving the symptoms of pain, inflammation, and any underlying complications that arise due to it.
Several major pharma and biotech companies are developing therapies for Acute pancreatitis. Currently, CalciMedica Inc. is leading the therapeutics market with its Acute pancreatitis drug candidates in the most advanced stage of clinical development.
Acute Pancreatitis Companies Actively Working in the Therapeutics Market Include
Lamassu Pharma LLC
And Many Others
Emerging and Marketed Acute Pancreatitis Therapies Covered in the Report Include:
Auxora: CalciMedica Inc.
REGN1500: Regeneron Pharmaceuticals
RABI-767: Lamassu Pharma LLC
And Many Other
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Acute Pancreatitis Competitive Intelligence Analysis
4. Acute Pancreatitis Market Overview at a Glance
5. Acute Pancreatitis Disease Background and Overview
6. Acute Pancreatitis Patient Journey
7. Acute Pancreatitis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Acute Pancreatitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Pancreatitis Unmet Needs
10. Key Endpoints of Acute Pancreatitis Treatment
11. Acute Pancreatitis Marketed Therapies
12. Acute Pancreatitis Emerging Drugs and Latest Therapeutic Advances
13. Acute Pancreatitis Seven Major Market Analysis
14. Attribute Analysis
15. Acute Pancreatitis Market Outlook (In US, EU5, and Japan)
16. Acute Pancreatitis Companies Active in the Market
17. Acute Pancreatitis Access and Reimbursement Overview
18. KOL Views on the Acute Pancreatitis Market
19. Acute Pancreatitis Market Drivers
20. Acute Pancreatitis Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Cushing’s Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Cushing’s Syndrome market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Cushing’s Syndrome market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States